Prenatal Intraportal Delivery of Polymeric Nanoparticles to Fetal Rhesus Monkeys ( Macaca mulatta )

Read full text
Authors: Alexandra S. Piotrowski-Daspit, Anna Lynn, David A. Eaton, Laura G. Bracaglia, Arianna I. Markey, Ryland D. Mortlock, David H. Stitelman, Michele L. Martinez, Charles C. Lee, H Kliman, Peter M. Glazer, Alice F. Tarantal
+1 more W. Mark Saltzman
Cited by: 2
References: 36

Abstract

Preliminary investigations focused on biodistribution of polymeric nanoparticles (NPs) shortly after ultrasound-guided delivery via the portal vein in early second-trimester fetal rhesus monkeys. Results demonstrated that poly(lactic-co-glycolic acid) (PLGA) NPs ( N = 3; 3 mg administered at 75–80 days gestational age) and poly(amine-co-ester)-polyethylene glycol (PACE-PEG) NPs ( N = 3; 3 mg at 75–80 days gestational age) distributed to fetal tissues when assessed 24 h post-administration. No adverse findings were observed. PLGA NPs were found primarily in the fetal liver and spleen, whereas PACE-PEG NPs showed more widespread biodistribution to a range of anatomical sites. In another fetal subset with PACE-PEG NPs ( N = 2; 90 days gestational age) assessed within 48-h post-administration, results demonstrated enhanced green fluorescent protein reporter mRNA expression in select tissues. These early-stage short-term studies suggest that polymeric NPs, particularly those composed of PACE-PEG, can be safely administered and are potential candidates for fetal delivery of therapeutic nucleic acids. While preliminary, these studies provide evidence to support further investigations in this species to address long-term safety and efficiency.

Fields of Study & Subjects

Ultrasound and Hyperthermia Applications RNA Interference and Gene Delivery Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Human Gene Therapy
Publisher
SAGE Publications
Volume
37
Issue
5-6
Pages
189–198
Publication date
5 February 2026
Language
EN